JP2024001364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024001364A5 JP2024001364A5 JP2023189255A JP2023189255A JP2024001364A5 JP 2024001364 A5 JP2024001364 A5 JP 2024001364A5 JP 2023189255 A JP2023189255 A JP 2023189255A JP 2023189255 A JP2023189255 A JP 2023189255A JP 2024001364 A5 JP2024001364 A5 JP 2024001364A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- less
- trehalose
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013646 | 2018-04-10 | ||
| IN201841013646 | 2018-04-10 | ||
| JP2020555387A JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
| PCT/IN2019/050292 WO2019198100A1 (en) | 2018-04-10 | 2019-04-10 | Antibody formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555387A Division JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024001364A JP2024001364A (ja) | 2024-01-09 |
| JP2024001364A5 true JP2024001364A5 (enExample) | 2024-04-11 |
| JP7793581B2 JP7793581B2 (ja) | 2026-01-05 |
Family
ID=68163986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555387A Pending JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
| JP2023189255A Active JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555387A Pending JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12030948B2 (enExample) |
| EP (1) | EP3773694A4 (enExample) |
| JP (2) | JP2021521159A (enExample) |
| CN (1) | CN112218654A (enExample) |
| AU (1) | AU2019253070A1 (enExample) |
| BR (1) | BR112020020707A2 (enExample) |
| CO (1) | CO2020013552A2 (enExample) |
| SG (1) | SG11202009874QA (enExample) |
| WO (1) | WO2019198100A1 (enExample) |
| ZA (1) | ZA202006263B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| BR112022022620A2 (pt) * | 2020-05-11 | 2022-12-20 | Medimmune Ltd | Formulações de anticorpos anti-il-33 |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| US20230340131A1 (en) * | 2020-11-12 | 2023-10-26 | Dr. Reddy’S Laboratories Limited | Stable aqueous high concentration formulation of integrin antibody |
| WO2022157806A1 (en) * | 2021-01-20 | 2022-07-28 | Dr. Reddy's Laboratories Limited | Freeze dried antibody formulations and methods thereof |
| WO2022234594A1 (en) * | 2021-05-07 | 2022-11-10 | Dr. Reddy’S Laboratories Limited | A method of improving stability of an antibody formulation |
| EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| CN120548195A (zh) | 2022-11-07 | 2025-08-26 | 上游生物公司 | 包含抗人类tslp受体抗体的药物组合物和其使用方法 |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2025041000A1 (en) * | 2023-08-21 | 2025-02-27 | Intas Pharmaceuticals Ltd. | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO346070B1 (no) * | 2003-02-10 | 2022-01-31 | Biogen Ma Inc | Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav. |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| US10040855B2 (en) * | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20210322549A1 (en) * | 2015-07-17 | 2021-10-21 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Natalizumab |
| WO2019147824A1 (en) * | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| WO2020104705A2 (en) * | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
-
2019
- 2019-04-10 EP EP19784340.2A patent/EP3773694A4/en active Pending
- 2019-04-10 JP JP2020555387A patent/JP2021521159A/ja active Pending
- 2019-04-10 WO PCT/IN2019/050292 patent/WO2019198100A1/en not_active Ceased
- 2019-04-10 US US17/045,380 patent/US12030948B2/en active Active
- 2019-04-10 SG SG11202009874QA patent/SG11202009874QA/en unknown
- 2019-04-10 AU AU2019253070A patent/AU2019253070A1/en not_active Abandoned
- 2019-04-10 BR BR112020020707-1A patent/BR112020020707A2/pt unknown
- 2019-04-10 CN CN201980037792.0A patent/CN112218654A/zh active Pending
-
2020
- 2020-10-08 ZA ZA2020/06263A patent/ZA202006263B/en unknown
- 2020-10-28 CO CONC2020/0013552A patent/CO2020013552A2/es unknown
-
2023
- 2023-11-06 JP JP2023189255A patent/JP7793581B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024001364A5 (enExample) | ||
| JP2010522208A5 (enExample) | ||
| HRP20250278T1 (hr) | Puferovane formulacije eksendina (9-39) | |
| JP2019536761A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| HRP20211417T1 (hr) | Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka | |
| JP2024099682A5 (enExample) | ||
| JP2012515221A5 (enExample) | ||
| JP2007262090A5 (enExample) | ||
| NO20053076L (no) | Farmasoytisk formulering med en uloselig aktiv forbindelse. | |
| NZ613809A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
| UA99815C2 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| RU2009148286A (ru) | Жидкая фармацевтическая композиция ботулинического токсина | |
| JP2020506924A5 (enExample) | ||
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| HRP20230462T1 (hr) | Supkutana formulacija protutijela anti-her2 | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| FI2608805T4 (fi) | NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA | |
| JP2005515237A5 (enExample) | ||
| JP2008535819A5 (enExample) | ||
| JP2007515469A5 (enExample) | ||
| AR063150A1 (es) | Formulaciones estables | |
| SI2236154T1 (en) | THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| JP2017516847A5 (enExample) |